m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00233)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
DUSP6
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Wilms tumor 1-associating protein (WTAP) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by WTAP | ||
Cell Line | mouse embryonic stem cells | Mus musculus |
Treatment: WTAP-/- ESCs
Control: Wild type ESCs
|
GSE145309 | |
Regulation |
|
logFC: -6.99E-01 p-value: 7.61E-15 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | m6A methyltransferase Wilms' tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation. WTAP enhanced Dual specificity protein phosphatase 6 (DUSP6) expression by increasing m6A levels of DUSP6 mRNA transcript, leading to oncogenic functions in NKTCL. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Malignant haematopoietic neoplasm | ICD-11: 2B33 | ||
Responsed Drug | Cisplatin | Approved | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | Normal NK cells (CD3-negative lymphocytes) | |||
SNK-6 | Nasal type extranodal NK/T-cell lymphoma | Homo sapiens | CVCL_A673 | |
YTS | Lymphoblastic leukemia/lymphoma | Homo sapiens | CVCL_D324 | |
Malignant haematopoietic neoplasm [ICD-11: 2B33]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | m6A methyltransferase Wilms' tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation. WTAP enhanced Dual specificity protein phosphatase 6 (DUSP6) expression by increasing m6A levels of DUSP6 mRNA transcript, leading to oncogenic functions in NKTCL. | |||
Responsed Disease | Malignant haematopoietic neoplasm [ICD-11: 2B33] | |||
Target Regulator | Wilms tumor 1-associating protein (WTAP) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Drug | Cisplatin | Approved | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | Normal NK cells (CD3-negative lymphocytes) | |||
SNK-6 | Nasal type extranodal NK/T-cell lymphoma | Homo sapiens | CVCL_A673 | |
YTS | Lymphoblastic leukemia/lymphoma | Homo sapiens | CVCL_D324 | |
Cisplatin
[Approved]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | m6A methyltransferase Wilms' tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation. WTAP enhanced Dual specificity protein phosphatase 6 (DUSP6) expression by increasing m6A levels of DUSP6 mRNA transcript, leading to oncogenic functions in NKTCL. | |||
Target Regulator | Wilms tumor 1-associating protein (WTAP) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Malignant haematopoietic neoplasm | ICD-11: 2B33 | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | Normal NK cells (CD3-negative lymphocytes) | |||
SNK-6 | Nasal type extranodal NK/T-cell lymphoma | Homo sapiens | CVCL_A673 | |
YTS | Lymphoblastic leukemia/lymphoma | Homo sapiens | CVCL_D324 | |
References